IPTACOPAN ASH UPDATE
Iptacopan monotherapy was superior to SoC for annualized
rate of clinical breakthrough hemolysis¹
Adjusted annual
Rate ratio
Arm
n/N²
rate, % (95% CI)
(95% CI)³
P value³
Rate of clinical
breakthrough
hemolysis1
Iptacopan
2/62
0.07 (0.02, 0.31)
0.10
0.0118
(0.02, 0.61)
Anti-C5 SoC
6/35
0.67 (0.26, 1.72)
■ Rate ratio of 0.10 means 10-fold lower rate of annualized clinical breakthrough hemolysis
1. Events that met the protocol-specified criteria for clinical breakthrough hemolysis. All hemolytic events were also reported as TEAEs, even if they did not meet the criteria for clinical breakthrough hemolysis. 2. n=number of patients with at
least one event, N=overall number of patients. 3. A negative binomial model was used for the comparison between treatment arms. P value is two-sided and unadjusted. TEAE = treatment-emergent adverse event.
17
IPTACOPAN ASH UPDATE | DECEMBER 13, 2022
NOVARTIS | Reimagining MedicineView entire presentation